Abstract：Objective To investigate the application value of traditional Chinese medicine directional penetration combined with Tofacitb in ankylosing spondylitis. Methods From February 2018 to August 2021, 70 patients with ankylosing spondylitis admitted to the Central Hospital of Xinyu Iron and Steel Group Co., Ltd. were selected as research objects, and divided into study group (n=35) and control group (n=35) according to the random number table method. The control group was treated with conventional antirheumatic drugs, while the study group was treated with traditional Chinese medicine directional penetration combined with Tofacitinib. The clinical efficacy, scores of visual analogue scale (VAS), Bath ankylosing spondylitis metroloty index (BASMI), Bath ankylosing spondylitis functional index (BASFI), Bath ankylosing spondylitis disease activity index (BASDAI), Pittsburgh sleep quality index scale (PSQI), generic quality of life inventory-74 (GQOL-74), erythrocyte sedimentation rate (ESR), high-sensitivity C-reactive protein (hs-CRP) and tumor necrosis factor-α, interleukin-1β (IL-1β), interferon-gamma (IFN-γ), bone alkaline phosphatase (BALP), bone gamma-carboxyglutamic-acid-containing proteins (BGP), bone mineral density and total incidence of adverse reactions were compared between the two groups. Results The total effective rate of the study group was higher than that of the control group, and the difference was statistically significant (P＜0.05). After 3 months of treatment, the scores of VAS, BASMI, BASFI, BASDAI and PSQI in the study group were lower than those in the control group, and the scores of GQOL-74 were higher than those in the control group, group, and the differences were statistically significant (P＜0.05). After 3 months of treatment, the levels of ESR, hs-CRP, TNF-α, IL-1β and BGP in the study group were lower than those in the control group, while the levels of IFN-γ, BALP and bone mineral density were higher than those in the control group, and the differences were statistically significant (P＜0.05). There was no significant difference in the total incidence of adverse reactions between the two groups (P＞0.05). Conclusion Directional penetration of traditional Chinese medicine combined with Tofacitb in the treatment of patients with ankylosing spondylitis can improve the curative effect, enhance the spinal function, improve the quality of life and reduce the level of inflammation, which is safe and should be paid attention to clinically.
符建平； 胡娟娟； 王强. 中医定向透药法联合托法替布在强直性脊柱炎的应用研究[J]. 中国当代医药, 2022, 29(19): 10-13转22.
FU Jianping； HU Juanjuan； WANG Qiang. Research on application of directional penetration of traditional Chinese medicine combined with Tofacib in ankylosing spondylitis. 中国当代医药, 2022, 29(19): 10-13转22.
京公网安备 11010502046607号